# Do GLP-1 Drugs Help You Live Longer? What Mortality Trials Found | Buy This GLP

See what SELECT and a review of 99,599 randomized participants found about deaths during GLP-1 treatment and what remains unknown about life expectancy.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/do-glp1-drugs-help-you-live-longer
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Do GLP-1 Drugs Help You Live Longer? What Mortality Trials Found

Randomized trials found fewer deaths during follow-up in the groups assigned to GLP-1 drugs. The findings do not tell us how many years of life treatment adds.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Deaths from any cause in SELECT · Semaglutide · 4.3% · Placebo · 5.2% · Median follow-up of 3.3 years

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A pooled analysis of randomized trials found fewer deaths during follow-up among people assigned to GLP-1 drugs.
-   In SELECT, 4.3% of participants assigned semaglutide died during follow-up, compared with 5.2% assigned placebo. Participants had established cardiovascular disease.
-   The studies do not estimate how many years treatment adds to a person’s life.

Randomized trials found fewer deaths during follow-up among people assigned to GLP-1 drugs. [The SELECT trial’s cardiovascular results](https://buythisglp.com/research/do-glp1-drugs-prevent-heart-attacks) apply to adults with overweight or obesity and established cardiovascular disease but without diabetes. A separate analysis of the same trial examined deaths from any cause.[\[2\]](https://buythisglp.com/research/do-glp1-drugs-help-you-live-longer#ref-2)[\[3\]](https://buythisglp.com/research/do-glp1-drugs-help-you-live-longer#ref-3)

## What SELECT found about deaths

Our [review of deaths after respiratory infection](https://buythisglp.com/research/do-glp1-drugs-lower-your-risk-from-covid-or-flu) covers a narrower outcome, including a secondary SELECT analysis. A result for deaths after infection does not establish whether the drug prevents infection.

Over a median of 3.3 years, 375 of 8,803 participants assigned semaglutide (4.3%) and 458 of 8,801 assigned placebo (5.2%) died. The hazard ratio was 0.81 (95% CI 0.71–0.93). The trial’s ordered testing plan stopped at an earlier secondary outcome, so all-cause mortality was not formally tested for superiority under that plan.[\[3\]](https://buythisglp.com/research/do-glp1-drugs-help-you-live-longer#ref-3)[\[4\]](https://buythisglp.com/research/do-glp1-drugs-help-you-live-longer#ref-4)

## What the pooled trials found

The [study of GLP-1 use after age 80](https://buythisglp.com/research/past-eighty-where-no-trial-goes) examined health records in adults with type 2 diabetes. Check whom a study enrolled before applying its mortality findings to another group.

A 2025 analysis of 99,599 participants across randomized trials reported an all-cause mortality incidence rate ratio of 0.88 (95% CI 0.84–0.92). The authors estimated that about 121 people would need treatment over the pooled follow-up to prevent one additional death, and about 66 to prevent one major cardiovascular event. These [numbers needed to treat](https://buythisglp.com/research/glp1-number-needed-to-treat) depend on whom the trials enrolled and how long they were observed.[\[2\]](https://buythisglp.com/research/do-glp1-drugs-help-you-live-longer#ref-2)

Why a record-based estimate can differ

A separate study of adults with obesity and without type 2 diabetes matched 12,123 people prescribed a GLP-1 drug with 12,123 controls. It reported a death hazard ratio of 0.23 (95% CI 0.15–0.34). Matching can account for recorded differences between the groups. Unmeasured differences may still affect the result, and the estimate cannot establish how much of the association came from the medication.[\[1\]](https://buythisglp.com/research/do-glp1-drugs-help-you-live-longer#ref-1)

## Frequently asked

Do GLP-1 drugs help people live longer?

A review of randomized trials found fewer deaths during follow-up. That evidence applies to the populations studied and does not give an estimate of years of life gained.

Who took part in SELECT?

SELECT enrolled adults with overweight or obesity and established cardiovascular disease who did not have diabetes. It compared semaglutide with placebo.

## Sources

1.  \[1\] Huang YN, et al. (2024). Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study Diabetes, Obesity and Metabolism. [PMID 39171569](https://pubmed.ncbi.nlm.nih.gov/39171569/)
2.  \[2\] Galli M, et al. (2025). Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients Journal of the American College of Cardiology. [PMID 40892610](https://www.jacc.org/doi/10.1016/j.jacc.2025.08.027)
3.  \[3\] Scirica BM, et al. (2024). The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial Journal of the American College of Cardiology. [Source](https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007)
4.  \[4\] European Medicines Agency (2024). Wegovy assessment report EMA. [Source](https://www.ema.europa.eu/en/documents/variation-report/wegovy-h-c-005422-ii-0017-epar-assessment-report-variation_en.pdf)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
